Tumor- or brain-derived gangliosides present during in vitro activation-induced settings (e.g., with anti-CD3 antibody) also associate with type-2 response shifts in CD4+ and CD8+ T cell populations by decreasing IFN-γ and often elevating IL-4 (79–81), along with increased apoptosis. The gene discussed is IFNG; the disease is neoplasm.